CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report
Publication Date
11-15-2023
Presented At:
Annual Meeting. Society for Neuro-Oncology (SNO)
Content Type
Presentation
Publisher's Site:
Citation
Ahluwalia, M., Ozair, A., Khosla, A., Patel, N., Elson, P., Murphy, E., Chao, S., Suh, J., Stevens, G., & Peereboom, D. (2023). CTNI-21: Phase I Study of BTK Inhibitor Ibrutinib with Temozolomide and Radiation in Newly-diagnosed Glioblastoma (EQUILIBRIUM): Final Trial Report. Neuro-Oncology, 25(Supplement_5), v78-v78. https://doi.org/10.1093/neuonc/noad179.0303